Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

(2018) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

(2018) Oscar Brück et al.   LEUKEMIA

Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making

(2018) James A. Kennedy et al.   Current Hematologic Malignancy Reports

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

(2017) Delphine Rea et al.   HAEMATOLOGICA

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages

(2017) Francesca Bellora et al.   JOURNAL OF IMMUNOLOGY

Current approach to the treatment of chronic myeloid leukaemia

(2017) Ivan Pasic et al.   LEUKEMIA RESEARCH

Immune control in chronic myeloid leukemia

(2017) Mette Ilander et al.   Oncotarget

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

(2017) Delphine Rea et al.   HAEMATOLOGICA

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission

(2017) Amy Hughes et al.   Frontiers in Immunology

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy

(2016) Noortje Thielen et al.   CLINICAL CANCER RESEARCH

The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses

(2016) Lindsay K. Ward-Kavanagh et al.   IMMUNITY

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

(2016) M Ilander et al.   LEUKEMIA

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

(2016) J L Steegmann et al.   LEUKEMIA

Immunological off-target effects of imatinib

(2016) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

(2016) Gianantonio Rosti et al.   Nature Reviews Clinical Oncology

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy

(2014) Mette Ilander et al.   PLoS One

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

(2014) Anna Kreutzman et al.   OncoImmunology

Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma

(2013) L. Calafiore et al.   ANNALS OF ONCOLOGY

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

(2013) H. M. Kantarjian et al.   BLOOD

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

(2013) S Mustjoki et al.   LEUKEMIA

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

(2013) Lisa Christiansson et al.   PLoS One

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

(2012) Dennis Lindau et al.   IMMUNOLOGY

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

(2012) S Mustjoki et al.   LEUKEMIA

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

(2012) Yoshiki Hayashi et al.   LEUKEMIA & LYMPHOMA

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

(2010) Peter Rohon et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

(2010) Julia Salih et al.   INTERNATIONAL JOURNAL OF CANCER

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

(2008) Devalingam Mahalingam et al.   CANCER TREATMENT REVIEWS

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

(2008) Oliver Hantschel et al.   LEUKEMIA & LYMPHOMA